Renal Cell Carcinoma. Translational Biology. Personalized Medicine and Novel Therapeutic Targets

Renal Cell Carcinoma. Translational Biology. Personalized Medicine and Novel Therapeutic Targets. Edited by R.A. Figlin, W.K. Rathmell, B.I. Rini. 2012, pp. 327, Eur 139.95, ISBN: 978-1-4614-2399-7. Springer Science + Business Media, New York, NY, USA.

This volume examines every major topic area in the modern era of renal carcinoma biology and treatment. The unique and intricate genetics of this cancer are highly distinct from most other tumors, and the advances made in this cancer beyond VHL biology have been intrinsically driven by discoveries from familial renal cell carcinomas linked with newer large scale genomic efforts in sporadic disease. These genetic findings fuel strategies to analyze and define sporadic tumors for greater accuracy in prognosis and prediction of response to therapy.

Additional topics include major new therapeutic strategies that harness these biological discoveries, in particular angiogenic, energy metabolism, chromatin remodeling, tumor microenvironment, and classical signaling pathways. This text will bring all of these avenues of investigation together for readers interested in understanding the dynamics of this field in the last decade and anticipating a continued steep trajectory in advancements toward the cure of this disease in its many manifestations.